AstraZeneca (LON:AZN) had its price objective increased by Deutsche Bank from GBX 5,600 ($75.37) to GBX 5,700 ($76.72) in a report released on Tuesday. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently commented on AZN. Investec lifted their price objective on AstraZeneca from GBX 4,900 ($65.95) to GBX 5,500 ($74.02) and gave the stock a buy rating in a research note on Monday, November 6th. J P Morgan Chase & Co set a GBX 4,200 ($56.53) price objective on AstraZeneca and gave the stock a neutral rating in a research note on Wednesday, August 9th. Barclays reaffirmed an overweight rating and set a GBX 5,500 ($74.02) price objective on shares of AstraZeneca in a research note on Monday, August 7th. Morgan Stanley reaffirmed an equal weight rating and set a GBX 5,000 ($67.29) price objective on shares of AstraZeneca in a research note on Friday, December 1st. Finally, Shore Capital reiterated a hold rating on shares of AstraZeneca in a report on Monday. Four analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. AstraZeneca currently has an average rating of Hold and a consensus price target of GBX 5,169 ($69.57).
Shares of AstraZeneca (LON:AZN) opened at GBX 4,708.61 ($63.37) on Tuesday. AstraZeneca has a 52 week low of GBX 4,007 ($53.93) and a 52 week high of GBX 5,520 ($74.29).
TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2017/12/08/deutsche-bank-boosts-astrazeneca-azn-price-target-to-gbx-5700.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
What are top analysts saying about AstraZeneca PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AstraZeneca PLC and related companies.